Clinical trials: Diseases of the Genitourinary System
Prostatic Hyperplasia
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
Patients who are currently symptomatic and have been diagnosed with BPH by a physician may qualify for this 20-week study. Patients must not be diabetic, must not have prostate cancer and must not have had any surgery to repair…
- Trial name
- NCT00044226
- Testing
- ML-04A
- Where
- 14 sites in United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Milkhaus Laboratory
Carcinoma, Renal Cell
Hepatic Monitoring for Pazopanib
Pazopanib is approved by the FDA and EMA as targeted therapy for the indication of advanced renal cell carcinoma (RCC). Hepatic safety events were observed in the pazopanib pivotal clinical trial and the U.S.
- Trial name
- NCT01449825
- Testing
- Pazopanib use, Use of sunitinib, bevacizumab, or sorafenib
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
The purpose of this trial with Zometa is to investigate the effect ZOMETA 4 mg (zoledronic acid for injection in 100mg solution ) has in preventing associated bone loss in prostate cancer patients with bone metastasis when…
- Trial name
- NCT00035997
- Testing
- Zometa
- Where
- 56 sites in United States
- Volunteers
- 261 people
- Sponsor
- Novartis Pharmaceuticals
Acute Kidney Injury
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
The purpose of this study is to determine whether THR-184 when administered around the time of cardiac surgery that requires cardiopulmonary bypass can prevent or ameliorate the development of acute kidney injury.
- Trial name
- NCT01830920
- Testing
- THR-184
- Where
- 41 sites in United States, Canada
- Volunteers
- 452 people
- Sponsor
- Thrasos Innovation, Inc.
Anemia, Kidney Disease, Chronic
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis
This prospective observational study will evaluate the safety and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic renal anemia on haemodialysis in maintenance ESA treatment.
- Trial name
- NCT01422824
- Where
- 6 sites in North Macedonia
- Volunteers
- 185 people
- Sponsor
- Hoffmann-La Roche
Genital Herpes Simplex Type 2
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
This study evaluates the reduction in viral shedding after vaccination with a new formulation of GEN-003 in subjects with genital HSV-2 infection.
- Trial name
- NCT02515175
- Testing
- Matrix-M2, GEN-003
- Where
- 8 sites in United States
- Volunteers
- 131 people
- Sponsor
- Genocea Biosciences, Inc.
Breast Cancer, Lung Cancer
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
- Conditions
- Breast Cancer, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer
- Trial name
- NCT02947165
- Testing
- NIS793, PDR001
- Where
- 12 sites in United States, Austria and 7 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Overactive Bladder (OAB), Refractory Overactive Bladder
Cefar URO - Symptomatic Treatment of Overactive Bladder
A Post-Market Prospective Clinical Investigation to collect PMCF data on the safety and performance of the Cefar URO device when using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the…
- Conditions
- Overactive Bladder (OAB), Refractory Overactive Bladder, Urinary Urgency and Frequency
- Trial name
- NCT06659536
- Testing
- Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device
- Where
- France
- Volunteers
- 53 people
- Sponsor
- DJO UK Ltd
Renal Cell Carcinoma
Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
The clinical outcome of advanced / metastatic renal cell carcinoma has been changed since targeted therapy being widely applied.
- Trial name
- NCT02776644
- Volunteers
- 1,349 people
- Sponsor
- Pfizer
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
PCA, Prostate Cancer
PSMA PET Combined With MRI for the Detection of PCa
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection…
- Conditions
- PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
- Trial name
- BiPASS (NCT07052214)
- Testing
- 68Ga-PSMA-11
- Where
- 18 sites in United States, Australia
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
HIV Infections
A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants
This study aims to assess any impact of VH4524184 on the pharmacokinetic (PK) profile of an ethinyl estradiol (EE) and norethindrone acetate (NEA) containing oral contraceptive (OC) administered to healthy adult female…
- Trial name
- NCT06310616
- Testing
- VH4524184, Loestrin
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received…
- Trial name
- NCT03834506
- Testing
- Pembrolizumab, Docetaxel, Prednisone
- Where
- 215 sites in United States, Argentina and 19 more
- Volunteers
- 1,030 people
- Sponsor
- Merck Sharp & Dohme LLC
Erectile Dysfunction, Sexual Dysfunction
Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction
The purpose of this study is to evaluate the efficacy and safety of dapoxetine compared to placebo in men with premature ejaculation and erectile dysfunction who are currently being treated with a phosphodiesterase-5 inhibitor…
- Trial name
- COUPLE (NCT01063855)
- Testing
- Dapoxetine, PDE5I (phosphodiesterase-5 inhibitor)
- Where
- 69 sites in United States, Argentina and 11 more
- Volunteers
- 495 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Neoplasm, Gynecologic
First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers
First in Human study, assessing the safety profile, the pharmacokinetics and preliminary antitumor activity of GM102, a new compound (a monoclonal antibody), in patients with previously treated gynecological cancers bearing the…
- Trial name
- NCT02978755
- Testing
- GM102, GM102 escalating doses
- Where
- 12 sites in Belgium, France and 1 more
- Volunteers
- 78 people
- Sponsor
- GamaMabs Pharma
HIV Infections
Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test
To determine the efficacy of an improved rapid diagnostic test using venous whole blood and fingerstick whole blood. The clinical performance of Reveal G4 Rapid HIV-1 Antibody Test will be determined by comparing the results with…
- Trial name
- NCT02190578
- Testing
- Reveal G4
- Where
- 4 sites in United States
- Volunteers
- 1,649 people, healthy volunteers welcome
- Sponsor
- MedMira Laboratories Inc.
Erectile Dysfunction
Assess Efficacy of Vardenafil 10mg in Erectile Dysfunction Within Intake of 6 Hours
Assess efficacy of vardenafil within 6 hours after intake
- Trial name
- NCT00668018
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Volunteers
- 887 people
- Sponsor
- Bayer
Primary Hyperoxaluria Type 1, End Stage Renal Disease
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
- Trial name
- PHYOX7 (NCT04580420)
- Testing
- DCR-PHXC
- Where
- 18 sites in United States, France and 8 more
- Volunteers
- 28 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.
- Conditions
- Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- Trial name
- PROSPER (NCT02003924)
- Testing
- Enzalutamide
- Where
- 397 sites in United States, Argentina and 30 more
- Volunteers
- 1,401 people
- Sponsor
- Pfizer
Prostatic Neoplasms
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.
- Trial name
- NCT02616185
- Testing
- PF-06755992, PF-06755990, TDS-IM Electroporation Device
- Where
- 19 sites in United States
- Volunteers
- 91 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.